We send the latest information from SMC Laboratories.
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad S…
Today, from our lineup of pathological models, we would like to introduce the imiquimod (IMQ)-induced dermatit…
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-…
In recent years, we have received many requests about our services, starting from the establishment of patholo…
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as M…
Today, we are excited to invite you to join our webinar that will be taking place on June 20 from 9:30 AM (JST…
If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such a…
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on …
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…